Test Price
2,800 AED✅ Home Collection Available
EZH2 Gene Leukemia, Lymphoblastic & Myeloid EZH2‑Related Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary: This Next‑Generation Sequencing (NGS) test interrogates the entire coding region of the EZH2 gene to detect pathogenic variants driving lymphoblastic and myeloid leukaemia. The assay delivers 99.9% diagnostic sensitivity through ISO 9001:2015‑accredited processing, in full compliance with the UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. We offer VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM to 11 PM) followed by a structured tele‑counselling session with a Consultant Medical Geneticist. For insurance verification or scheduling, contact WhatsApp +971 54 548 8731.
Test Overview & Methodology
The EZH2 NGS panel sequences the complete coding region and splice‑site boundaries of EZH2 to detect gain‑of‑function, loss‑of‑function, and structural rearrangements implicated in lymphoid and myeloid malignancies. The assay supports precise molecular sub‑classification, targeted therapy selection, and clinical trial eligibility assessment in haematological oncology.
| Feature | EZH2 NGS Panel (DNA Labs UAE) | Conventional Sanger Sequencing |
|---|---|---|
| Methodology | Next‑Generation Sequencing – full coding region + splice sites | Sanger sequencing of selected hotspot exons only |
| Diagnostic Sensitivity | 99.9% (detects point mutations, indels, CNVs, deep intronic variants) | ~85% (misses large deletions, duplications, and deep intronic changes) |
| Turnaround Time | 3–4 Weeks with ISO cold‑chain logistics | 4–6 Weeks (often outsourced to reference laboratories) |
| Regulatory Compliance | Full DHA, PDPL, Federal Law No. 2 of 2019 | Variable; may not satisfy local data privacy statutes |
Physician Insight & Safety Protocols
"The EZH2 mutational landscape provides critical prognostic and therapeutic information in acute leukaemia, but the result must be integrated with blast morphology, immunophenotyping, cytogenetics, and the patient's clinical trajectory. A negative sequencing report does not rule out malignancy, and any identified variant should be reviewed by a board‑certified haematopathologist before treatment decisions are altered. Self‑modification of chemotherapy or targeted agents based solely on this genetic report is strongly discouraged."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Safety Advisory
Genetic test results inform but do not replace clinical judgement. Do not discontinue, reduce, or initiate any chemotherapeutic regimen, targeted therapy, or supportive medication without explicit written instruction from your treating haematologist. Laboratory findings alone are insufficient grounds for altering prescribed treatment protocols.
Exclusion Criteria & Emergency Red Flags
- Active uncontrolled systemic infection – postpone elective phlebotomy until infection resolves.
- Severe anaemia (haemoglobin <7 g/dL) or coagulopathy – consult supervising specialist before sampling.
- Blood transfusion or platelet transfusion within the preceding 14 days may dilute circulating leukaemic DNA; inform the laboratory.
- Emergency Signs: Sudden fever >38.5°C, unexplained widespread bruising or petechiae, acute confusion, or respiratory distress – proceed to the nearest emergency department immediately.
Patient FAQ & Clinical Guidance
1. What specific mutations does the EZH2 NGS test identify, and how do those results shape my leukaemia management?
The assay detects point mutations, small insertions and deletions, copy‑number alterations, and splice‑site variants across the entire EZH2 coding sequence. These findings enable your oncologist to assign a precise molecular subtype, select appropriate targeted therapies such as EZH2 inhibitors, and determine eligibility for biomarker‑driven clinical trials.
2. Is home blood collection safe and legally permitted for genetic testing under UAE regulations?
Yes. Our ISO‑certified phlebotomists operate under DHA home‑care permits and utilise validated cold‑chain transport to preserve nucleic acid integrity. The entire process complies with Federal Decree‑Law No. 45 of 2021 (PDPL) and Federal Law No. 2 of 2019, ensuring your personal genetic data remains sovereign and protected.
3. How are my results delivered, and is a genetic counselling session included?
Results are uploaded to a HIPAA‑aligned, encrypted patient portal within the stated turnaround time. Every report includes a complimentary 30‑minute tele‑counselling session with our Consultant Medical Geneticist to review findings, discuss implications for first‑degree relatives, and coordinate next clinical steps.
UAE Regulatory & Data Privacy Adherence
- ISO 9001:2015 Certified Laboratory – Certificate: INT/EGQ/2509DA/3139
- DHA Facility License Number: 1143
- Full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Clinical safety and patient consent governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability
- All testing performed on an Illumina Next‑Generation Sequencing platform with validated bioinformatics pipelines
Clinical & Logistical Metadata
| Test Name | EZH2 Gene Sequencing – Leukaemia Panel (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (Peripheral) – EDTA Tube; VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM – 11 PM |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Coding Region & Splice‑Site Analysis |
| ICD-10-CM Code | C91.0, C92.0 |
| LOINC Code | 92736-8 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians